You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 3, 2024

NOLVADEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Nolvadex, and when can generic versions of Nolvadex launch?

Nolvadex is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in NOLVADEX is tamoxifen citrate. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nolvadex

A generic version of NOLVADEX was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NOLVADEX?
  • What are the global sales for NOLVADEX?
  • What is Average Wholesale Price for NOLVADEX?
Summary for NOLVADEX
US Patents:0
Applicants:1
NDAs:1
Clinical Trials: 75
DailyMed Link:NOLVADEX at DailyMed
Drug patent expirations by year for NOLVADEX
Recent Clinical Trials for NOLVADEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eli Lilly and CompanyPhase 2
Jose Pablo LeonePhase 2
Translational Breast Cancer Research Consortium (TBCRC)Phase 2

See all NOLVADEX clinical trials

US Patents and Regulatory Information for NOLVADEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca NOLVADEX tamoxifen citrate TABLET;ORAL 017970-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca NOLVADEX tamoxifen citrate TABLET;ORAL 017970-002 Mar 21, 1994 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NOLVADEX

See the table below for patents covering NOLVADEX around the world.

Country Patent Number Title Estimated Expiration
Germany 1768020 ⤷  Sign Up
Denmark 118655 ⤷  Sign Up
Switzerland 538447 Verfahren zur Herstellung der cis- oder trans-Isomeren von Alkenderivaten ⤷  Sign Up
Switzerland 446289 Verfahren zur Herstellung von Alkenderivaten ⤷  Sign Up
United Kingdom 1064629 ⤷  Sign Up
Belgium 678807 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.